论文部分内容阅读
目的探讨病毒性心肌炎患儿血清高迁移率蛋白-1(HMGB1)和内脂素的变化及临床意义。方法采用ELISA法测定52例病毒性心肌炎患儿血清HMGB1和内脂素水平,同时检测磷酸肌酸激酶同工酶(CK-MB),并与36例健康儿童作对照。结果病毒性心肌炎治疗前血清HMGB1和内脂素水平明显高于治疗2周后及对照组(P<0.01);治疗2周后HMGB1和内脂素水平与对照组比较,差异无统计学意义(P>0.05);病毒性心肌炎患儿HMGB1与内脂素、CK-MB呈正相关(r=0.73,0.79,P<0.05),内脂素与CK-MB亦呈正相关(r=0.82,P<0.05)。结论 HMGB1和内脂素可能参与病毒性心肌炎的发生、发展,并可作为病情判断及预后的观察指标。
Objective To investigate the changes and clinical significance of serum high mobility group-1 (HMGB1) and visfatin in children with viral myocarditis. Methods Serum levels of HMGB1 and visfatin were measured in 52 children with viral myocarditis by ELISA. Meanwhile, creatine phosphokinase (CK-MB) was measured and compared with 36 healthy children. Results The serum levels of HMGB1 and visfatin in patients with viral myocarditis before treatment were significantly higher than those in the control group after 2 weeks of treatment (P <0.01). After 2 weeks of treatment, the levels of HMGB1 and visfatin were not significantly different from those in the control group P <0.05). There was a positive correlation between HMGB1 and visfatin and CK-MB in children with viral myocarditis (r = 0.73,0.79, P <0.05) 0.05). Conclusion HMGB1 and visfatin may be involved in the occurrence and development of viral myocarditis and can be used as an indicator of disease judgment and prognosis.